Exchange: NASDAQ·Updated 10:01 AM EDT
LPCN logo

LPCN Lipocine Inc

$2.43
$0.01
(0.41%)
Today
Reported EarningsAug 4
Mkt Cap$19.95M
Vol6,829.00

About LPCN

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.
51

Neutral Sentiment

How do you feel about LPCN?

Advertisement|Remove ads.